

Corrigendum

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

J Ryan^{1,2}, A Tivnan^{1,2}, J Fay^{1,2}, K Bryan^{1,2}, M Meehan^{1,2}, L Creevey^{1,2}, J Lynch^{1,2}, IM Bray^{1,2}, A O'Meara², L Tracey³, AM Davidoff³ and RL Stallings^{1,2}

¹Department of Molecular and Cellular Therapeutics, Cancer Genetics Research Group, Royal College of Surgeons in Ireland (RCSI), York House, York Street, Dublin 2, Ireland; ²National Children's Research Centre (NCRC), Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland; ³Department of Surgery, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA

British Journal of Cancer (2012) **107**, 1203. doi:10.1038/bjc.2012.425 www.bjcancer.com
© 2012 Cancer Research UK

Correction to: *British Journal of Cancer* (2012) **107**, 967–976.
doi:10.1038/bjc.2012.356

The authors and publishers are now happy to present the complete, full authorship above.

Upon publication online and in print, the authors realised that a contributor to the original data for this manuscript had been omitted from the authorship of the final paper.